The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | Iptacopan for paroxysmal nocturnal hemoglobinuria
Regis Peffault de Latour
• 2 Sep 2020
Régis Peffault de Latour, MD, PhD, Saint-Louis Hospital, Paris, France, discusses the results of a study (NCT03439839) evaluating the safety and efficacy of iptacopan, a factor B inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) in combination with standard treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
